Firefly Neuroscience (AIFF) Cash & Equivalents (2010 - 2026)

Firefly Neuroscience's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $3.1 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 67.24% year-over-year to $3.1 million; the TTM figure through Mar 2026 stood at $3.1 million (down 67.24% YoY), while the FY2025 annual figure was $2.7 million, up 51.77% from the prior year.
• Cash & Equivalents was $3.1 million for Q1 2026 at Firefly Neuroscience, up from $2.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $9.5 million in Q1 2025 to a low of $58000.0 in Q4 2022.
• Historically, Cash & Equivalents has averaged $2.3 million across 5 years, with a median of $1.6 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents tumbled 98.82% in 2022, then jumped 3594.83% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $58000.0 in 2022, then surged by 3594.83% to $2.1 million in 2023, then fell by 15.54% to $1.8 million in 2024, then soared by 51.77% to $2.7 million in 2025, then grew by 13.83% to $3.1 million in 2026.
• The last three Cash & Equivalents figures came in at $3.1 million (Q1 2026), $2.7 million (Q4 2025), and $4.3 million (Q3 2025), per Business Quant data.